CompletedNot Applicable

Cardea SOLOTM for Paroxysmal Atrial Fibrillation Diagnosis in ESUS Patients With Left Atrial Enlargement

South Korea257 participantsStarted 2022-11-01

Plain-language summary

The aim of the study is to evaluate the efficacy and safety of the Cardea SOLO Compared to 12 lead EKG for Paroxysmal Atrial Fibrillation Diagnosis in ESUS patients with Left Atrial Enlargement.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Transient cerebral ischemic attack
✕. Active cancer
✕. Heart embolism, stroke of major heart embolism, stroke high-risk disease
✕. Left atrial thrombus
✕. Left ventricular thrombus
✕. Sick sinus syndrome
✕. Myocardiac infarction in 1 month
✕. Rheumatic left atrioventricular valve or aortic valve disease

What they're measuring

Patients number with AF over 30 seconds of cardea SOLO / with AF with 1 time of 12 lead EKG

Timeframe: 30 seconds

Trial details

NCT IDNCT05431972

SponsorAsan Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-13

View on ClinicalTrials.gov More Embolic Stroke of Undetermined Source trials